Medicinal, Psychological, and Health Research Journal (MPHRJ)

The Efficacy of Cognitive Behavioral Therapy (CBT) in Treating Treatment-Resistant Depression: Mechanisms and Long-Term Outcomes

Document Type : Original Article

Author

Sunay Güngör

Gümüşhane University, Faculty of Literature, Department of Psychology, Gümüşhane- TURKIYE

https://doi.org/10.22034/mphrj.2026.591046.1108
Abstract
Background: Treatment-resistant depression (TRD) represents a significant clinical challenge, affecting approximately 30% of individuals with major depressive disorder who fail to respond to conventional antidepressant pharmacotherapy. Cognitive Behavioral Therapy (CBT) has emerged as a promising intervention for this population, yet the specific mechanisms and long-term efficacy remain incompletely understood. Objective: This study systematically examines the efficacy of CBT in treating TRD, investigating psychological and neurobiological mechanisms of change and evaluating long-term outcomes.

Methods: A comprehensive review was conducted of randomized controlled trials, meta-analyses, and key observational studies published between 2000 and 2025, identified from PubMed, PsycINFO, and Cochrane Library databases. Special attention was given to studies examining CBT as an augmentation strategy, sudden gains in treatment response, and neural correlates of therapeutic change.

Results: Robust evidence supports CBT as an effective augmentation strategy for TRD, with effect sizes comparable to pharmacological augmentation approaches (ES = 1.58, 95% CI: 1.09–2.07). Psychological flexibility emerged as a key mechanism predicting long-term outcomes at 12-month follow-up. Neuroimaging findings reveal both treatment-responsive prefrontal and parietal regions and treatment-resistant cerebellar regions, suggesting that CBT may not uniformly normalize all neural abnormalities. Long-term relapse rates among TRD patients receiving CBT augmentation range from 25-50% at 12 months, with the greatest durability observed in those who achieve sudden therapeutic gains early in treatment.

Conclusion: CBT constitutes an essential component of the TRD treatment arsenal, offering durable benefits beyond pharmacotherapy alone. Future research must prioritize standardized TRD definitions, biomarker-driven personalization, and scalable delivery models to optimize clinical implementation.

Graphical Abstract

The Efficacy of Cognitive Behavioral Therapy (CBT) in Treating Treatment-Resistant Depression: Mechanisms and Long-Term Outcomes

Keywords

Treatment-Resistant Depression
Cognitive Behavioral Therapy
Augmentation Strategy
Psychological Flexibility
Long-Term Outcomes
Subjects
[1]    Abel, A., Hayes, A. M., & Kuyken, W. (2023). Sudden gains in cognitive-behavior therapy for treatment-resistant depression: Processes of change. Journal of Consulting and Clinical Psychology.
[2]    Javad Jaberi, M., & Kianersi, N. (2025). The efficacy of cognitive behavioral therapy (CBT) in treating treatment-resistant depression. Humanistic Studies and Social Researches. 
[3]    Matthews, K., & Nutt, D. J. (2023). Model-based planning is unaffected by ketamine, antidepressant and internet delivered cognitive behavioural therapy treatments in depression. Neuro psychopharmacology.
[4]    Strege, M. V., Richey, J. A., & Siegle, G. J. (2024). Trying to name what doesn't change: Neural nonresponse to cognitive therapy for depression. Psychological Medicine, 54(1), 136-147.
[5]    Wilkinson, S. T., Wright, D., Fasula, M. K., Fenton, L., Gripp, M., Ostroff, R. B., & Sanacora, G. (2017). Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychotherapy and Psychosomatics, 86(3), 162-167.
[6]    Yasinski, C., Hayes, A. M., Ready, C. B., Abel, A., Görg, N., & Kuyken, W. (2023). Processes of change in cognitive behavioral therapy for treatment-resistant depression: Psychological flexibility, rumination, avoidance, and emotional processing. Behavior Research and Therapy.
[7]    Scott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., Young, A. H., & Strawbridge, R. (2023). Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. Journal of Psychopharmacology, 37(3), 268-278.
[8]    DeRubeis, R. J., Siegle, G. J., & Hollon, S. D. (2008). Cognitive therapy vs. medications for depression: Treatment outcomes and neural mechanisms. Nature Reviews Neuroscience, 9(10), 788-796.
[9]    Wilkinson, S. T., Wright, D., Fasula, M. K., Fenton, L., Gripp, M., Ostroff, R. B., & Sanacora, G. (2017). Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychotherapy and Psychosomatics, 86(3), 162-167.
[10] Scott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., Young, A. H., & Strawbridge, R. (2023). Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression. Journal of Psychopharmacology, 37(3), 268-278.
[11] Strege, M. V., Richey, J. A., & Siegle, G. J. (2024). Trying to name what doesn't change: Neural nonresponse to cognitive therapy for depression. Psychological Medicine, 54(1), 136-147.
[12] Beck, A. T. (2008). The evolution of the cognitive model of depression and its neurobiological correlates. American Journal of Psychiatry, 165(8), 969-977.
[13] Clark, D. A., & Beck, A. T. (2010). Cognitive theory and therapy of anxiety and depression: Convergence with neurobiological findings. Trends in Cognitive Sciences, 14(9), 418-424.
[14] Goldapple, K., Segal, Z., Garson, C., Lau, M., Bieling, P., Kennedy, S., & Mayberg, H. (2004). Modulation of cortical-limbic pathways in major depression: Treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry, 61(1), 34-41.
[15] Mayberg, H. S. (2003). Modulating dysfunctional limbic-cortical circuits in depression: Towards development of brain-based algorithms for diagnosis and optimized treatment. British Medical Bulletin, 65(1), 193-207.
[16] Frewen, P. A., Dozois, D. J. A., & Lanius, R. A. (2008). Neuroimaging studies of psychological interventions for mood and anxiety disorders: Empirical and methodological review. Clinical Psychology Review, 28(2), 228-246.
[17] Sankar, A., Scott, J., Gregory, S., & Friston, K. (2018). Changes in brain structure and function following cognitive behavioral therapy for depression: A systematic review. Journal of Affective Disorders, 225, 699-712.
[18] Marwood, L., Wise, T., Perkins, A. M., & Cleare, A. J. (2018). Meta-analyses of the neural effects of psychological treatments for depression and anxiety: A systematic review. Journal of Affective Disorders, 240, 159-170.
[19] Judd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., ... & Keller, M. B. (1998). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Archives of General Psychiatry, 55(8), 694-700.
[20] Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., ... & Rush, A. J. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: A STAR*D report. Psychological Medicine, 40(1), 41-50.
[21] Siegle, G. J., Granholm, E., Ingram, R. E., & Matt, G. E. (2001). Pupillary and reaction time measures of sustained processing of negative information in depression. Biological Psychiatry, 49(7), 624-636.
[22] Siegle, G. J., Thompson, W., Carter, C. S., Steinhauer, S. R., & Thase, M. E. (2007). Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: Related and independent features. Biological Psychiatry, 61(2), 198-209.
[23] Menon, V. (2011). Large-scale brain networks and psychopathology: A unifying triple network model. Trends in Cognitive Sciences, 15(10), 483-506.
[24] Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O'Reardon, J. P., ... & Gallop, R. (2005). Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Archives of General Psychiatry, 62(4), 417-422.
[25] Dobson, K. S., Hollon, S. D., Dimidjian, S., Schmaling, K. B., Kohlenberg, R. J., Gallop, R. J., ... & Jacobson, N. S. (2008). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. Journal of Consulting and Clinical Psychology, 76(3), 468-477.
Medicinal, Psychological, and Health Research Journal (MPHRJ)
Volume 2, Issue 6
November and December 2026
Pages 438-451

Home

Editorial Board

Guide for Authors

Submit Manuscript

Contact Us